Arcato Advances Non-Opioid Oral Pain Treatment
Arcato Laboratories, Inc. ( https://www.arcato-labs.com/ ) today simultaneously announced successful top line results from its first-in-human Phase 1 study of ARC-001 Gel in patients following third molar (wisdom tooth) extraction surgery, as well as the closing of its first round of financing. ARC-001 Gel is a novel, proprietary, sustained-release, single-dose gel formulation combining three well-characterized, non-addictive anesthetics: benzocaine, lidocaine, and bupivacaine. The novel formulation of ARC-001 Gel allows for a one-time local administration into the tooth socket following surgical extraction, with a pharmacokinetic profile supporting the potential for pain relief for up to 7 days. ARC-001 Gel does not require an injection or a needle; the gel is easily administered directly into the extraction socket. The Phase 1 primary endpoint of safety was achieved, supporting further Phase 2/3 development. Exploratory efficacy endpoints sugg...
